{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:49:03Z","timestamp":1794588543642,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["676408"],"award-info":[{"award-number":["676408"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) and atypical parkinsonisms (APD) have overlapping symptoms challenging an early diagnosis. Diagnostic accuracy is important because PD and APD have different prognosis and response to treatment. We aimed to identify diagnostic inflammatory biomarkers of PD and APD in cerebrospinal fluid (CSF) using the multiplex proximity extension assay (PEA) technology and to study possible correlations of biomarkers with disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CSF from a longitudinal cohort study consisting of PD and APD patients (PD,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200944; multiple system atrophy (MSA),\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914; vascular parkinsonism (VaP),\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099; and PD with VaP,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097) and controls (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925) were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Concentrations of CCL28 were elevated in PD compared to controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001). Five other biomarkers differentiated both MSA and PD from controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and 10 biomarkers differentiated MSA from controls, of which two proteins, i.e. beta nerve growth factor (\u03b2-NGF) and Delta and Notch like epidermal growth factor-related receptor (DNER), were also present at lower levels in MSA compared to PD (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032). Two biomarkers (MCP-1 and MMP-10) positively correlated with PD progression (rho &gt;\u20090.650;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PEA technique identified potential new CSF biomarkers to help to predict the prognosis of PD. Also, we identified new candidate biomarkers to distinguish MSA from PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-020-1608-8","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T07:02:37Z","timestamp":1579244557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Inflammation biomarker discovery in Parkinson\u2019s disease and atypical parkinsonisms"],"prefix":"10.1186","volume":"20","author":[{"given":"Anna","family":"Santaella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bea","family":"Kuiperij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouke","family":"van Rumund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne A. J.","family":"Esselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain J.","family":"van Gool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan R.","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-7876","authenticated-orcid":false,"given":"Marcel M.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"issue":"9996","key":"1608_CR1","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"issue":"4","key":"1608_CR2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ana.20226","volume":"56","author":"GW Ross","year":"2004","unstructured":"Ross GW, Petrovitch H, Abbott RD, Nelson J, Markesbery W, Davis D, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol. 2004;56(4):532\u20139.","journal-title":"Ann Neurol"},{"issue":"2","key":"1608_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197\u2013211.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1608_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","volume":"5","author":"E Tolosa","year":"2006","unstructured":"Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5(1):75\u201386.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1608_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00702-017-1700-4","volume":"124","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Kassubek J, Csoti I, Ehret R, Herbst H, Wellach I, et al. Differentiation of atypical Parkinson syndromes. J Neural Transm (Vienna). 2017;124(8):997\u20131004.","journal-title":"J Neural Transm (Vienna)"},{"key":"1608_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","volume":"50","author":"D Devos","year":"2013","unstructured":"Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, et al. Colonic inflammation in Parkinson's disease. Neurobiol Dis. 2013;50:42\u20138.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1608_CR7","doi-asserted-by":"publisher","first-page":"a009381","DOI":"10.1101\/cshperspect.a009381","volume":"2","author":"RL Mosley","year":"2012","unstructured":"Mosley RL, Hutter-Saunders JA, Stone DK, Gendelman HE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2(1):a009381.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1608_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/B978-0-12-398314-5.00004-0","volume":"88","author":"KU Tufekci","year":"2012","unstructured":"Tufekci KU, Meuwissen R, Genc S, Genc K. Inflammation in Parkinson's disease. Adv Protein Chem Struct Biol. 2012;88:69\u2013132.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"6","key":"1608_CR9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in Neurodegeneration. Cell. 2010;140(6):918\u201334.","journal-title":"Cell."},{"issue":"3","key":"1608_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.nbd.2010.04.020","volume":"39","author":"KD van Dijk","year":"2010","unstructured":"van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis. 2010;39(3):229\u201341.","journal-title":"Neurobiol Dis"},{"key":"1608_CR11","doi-asserted-by":"crossref","unstructured":"Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, et al. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2019;0:1-6.","DOI":"10.1136\/jnnp-2018-320151"},{"issue":"2","key":"1608_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s00415-014-7568-4","volume":"262","author":"MB Aerts","year":"2015","unstructured":"Aerts MB, Esselink RA, Abdo WF, Meijer FJ, Drost G, Norgren N, et al. Ancillary investigations to diagnose parkinsonism: a prospective clinical study. J Neurol. 2015;262(2):346\u201356.","journal-title":"J Neurol"},{"issue":"12","key":"1608_CR13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"6","key":"1608_CR14","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1474-4422(16)00116-2","volume":"15","author":"RB Postuma","year":"2016","unstructured":"Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, et al. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016;15(6):546\u20138.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1608_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"key":"1608_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.12.030","volume":"49","author":"I Rektor","year":"2018","unstructured":"Rektor I, Bohnen NI, Korczyn AD, Gryb V, Kumar H, Kramberger MG, et al. An updated diagnostic approach to subtype definition of vascular parkinsonism - recommendations from an expert working group. Parkinsonism Relat Disord. 2018;49:9\u201316.","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"1608_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mds.20083","volume":"19","author":"JC Zijlmans","year":"2004","unstructured":"Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19(6):630\u201340.","journal-title":"Mov Disord"},{"issue":"5","key":"1608_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neurobiolaging.2006.03.010","volume":"28","author":"WF Abdo","year":"2007","unstructured":"Abdo WF, Bloem BR, Van Geel WJ, Esselink RAJ, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging. 2007;28(5):742\u20137.","journal-title":"Neurobiol Aging"},{"key":"1608_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fneur.2015.00091","volume":"6","author":"MK Herbert","year":"2015","unstructured":"Herbert MK, Aerts MB, Beenes M, Norgren N, Esselink RAJ, Bloem BR, et al. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Front Neurol. 2015;6:91.","journal-title":"Front Neurol"},{"issue":"1","key":"1608_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","volume":"20","author":"MK Herbert","year":"2014","unstructured":"Herbert MK, Eeftens JM, Aerts MB, Esselink RA, Bloem BR, Kuiperij HB, et al. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord. 2014;20(1):112\u20135.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1608_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neurobiolaging.2013.07.005","volume":"35","author":"M M\u00fcller","year":"2014","unstructured":"M\u00fcller M, Kuiperij HB, Claassen JA, K\u00fcsters B, Verbeek MM. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 2014;35(1):152\u20138.","journal-title":"Neurobiol Aging"},{"key":"1608_CR22","doi-asserted-by":"crossref","unstructured":"Schwenkenbecher P, Janssen T, Wurster U, Konen FF, Neyazi A, Ahlbrecht J, et al. The influence of blood contamination on cerebrospinal fluid diagnostics. Front Neurol. 2019;10(584):1-9.","DOI":"10.3389\/fneur.2019.00584"},{"issue":"1","key":"1608_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1042\/BST20160262","volume":"45","author":"H Lee","year":"2017","unstructured":"Lee H, James WS, Cowley SA. LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. Biochem Soc Trans. 2017;45(1):131\u20139.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"1608_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12881-018-0547-3","volume":"19","author":"C Fardell","year":"2018","unstructured":"Fardell C, Zettergren A, Ran C, Carmine Belin A, Ekman A, Sydow O, et al. S100B polymorphisms are associated with age of onset of Parkinson's disease. BMC Med Genet. 2018;19(1):42.","journal-title":"BMC Med Genet"},{"issue":"7","key":"1608_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/mds.20820","volume":"21","author":"DA Grimes","year":"2006","unstructured":"Grimes DA, Han F, Panisset M, Racacho L, Xiao F, Zou R, et al. Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord. 2006;21(7):906\u20139.","journal-title":"Mov Disord"},{"key":"1608_CR26","doi-asserted-by":"crossref","unstructured":"Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, et al. The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegeneration. 2016;5(16):1-6.","DOI":"10.1186\/s40035-016-0063-3"},{"key":"1608_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.intimp.2017.08.012","volume":"51","author":"T Mohan","year":"2017","unstructured":"Mohan T, Deng L, Wang BZ. CCL28 chemokine: an anchoring point bridging innate and adaptive immunity. Int Immunopharmacol. 2017;51:165\u201370.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"1608_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.neuint.2012.08.001","volume":"61","author":"JX Liu","year":"2012","unstructured":"Liu JX, Cao X, Liu Y, Tang FR. CCL28 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus. Neurochem Int. 2012;61(7):1094\u2013101.","journal-title":"Neurochem Int"},{"key":"1608_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fnins.2015.00507","volume":"9","author":"DG Walker","year":"2016","unstructured":"Walker DG, Lue L-F, Serrano G, Adler CH, Caviness JN, Sue LI, et al. Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. Front Neurosci. 2016;9:507.","journal-title":"Front Neurosci"},{"issue":"6","key":"1608_CR30","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson\u2019s Disease. Cell. 2016;167(6):1469\u201380.e12.","journal-title":"Cell"},{"issue":"6","key":"1608_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10517-017-3700-7","volume":"162","author":"VA Petrov","year":"2017","unstructured":"Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, et al. Analysis of gut microbiota in patients with Parkinson's disease. Bull Exp Biol Med. 2017;162(6):734\u20137.","journal-title":"Bull Exp Biol Med"},{"issue":"4","key":"1608_CR32","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ije\/dys052","volume":"41","author":"F Fang","year":"2012","unstructured":"Fang F, Wirdefeldt K, Jacks A, Kamel F, Ye W, Chen H. CNS infections, sepsis and risk of Parkinson's disease. Int J Epidemiol. 2012;41(4):1042\u20139.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"1608_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/WNR.0000000000000726","volume":"28","author":"Ji-Hye Yoon","year":"2017","unstructured":"Yoon JH, Ann EJ, Kim MY, Ahn JS, Jo EH, Lee HJ, et al. Parkin mediates neuroprotection through activation of Notch1 signaling. Neuroreport. 2017;28(4):181\u20136.","journal-title":"NeuroReport"},{"key":"1608_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-1139-4_1","volume":"1187","author":"S Yamamoto","year":"2014","unstructured":"Yamamoto S, Schulze KL, Bellen HJ. Introduction to notch signaling. Methods Mol Biol. 2014;1187:1\u201314.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"1608_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12031-007-9032-8","volume":"35","author":"TH Wang","year":"2008","unstructured":"Wang TH, Feng ZT, Wei P, Li H, Shi ZJ, Li LY. Effects of pcDNA3-beta-NGF gene-modified BMSC on the rat model of Parkinson's disease. J Mol Neurosci. 2008;35(2):161\u20139.","journal-title":"J Mol Neurosci"},{"issue":"2","key":"1608_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/0014-4886(91)90172-9","volume":"113","author":"V Silani","year":"1991","unstructured":"Silani V, Pizzuti A, Falini A, Borsani G, Rugarli EI, Melo CA, et al. Beta-nerve growth factor (beta-NGF) mRNA expression in the parkinsonian adrenal gland. Exp Neurol. 1991;113(2):166\u201370.","journal-title":"Exp Neurol"},{"issue":"1","key":"1608_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0304-3940(91)90354-V","volume":"131","author":"SJ Allen","year":"1991","unstructured":"Allen SJ, MacGowan SH, Treanor JJ, Feeney R, Wilcock GK, Dawbarn D. Normal beta-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci Lett. 1991;131(1):135\u20139.","journal-title":"Neurosci Lett"},{"issue":"11","key":"1608_CR38","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86(11):1240\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10103","key":"1608_CR39","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375.","journal-title":"Lancet"},{"key":"1608_CR40","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fimmu.2018.00586","volume":"9","author":"IM Rea","year":"2018","unstructured":"Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol. 2018;9:586.","journal-title":"Front Immunol"},{"issue":"1","key":"1608_CR41","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41598-018-19807-y","volume":"8","author":"W-J Lee","year":"2018","unstructured":"Lee W-J, Liao Y-C, Wang Y-F, Lin IF, Wang S-J, Fuh J-L. Plasma MCP-1 and cognitive decline in patients with Alzheimer\u2019s disease and mild cognitive impairment: a two-year follow-up study. Sci Rep. 2018;8(1):1280.","journal-title":"Sci Rep"},{"issue":"25","key":"1608_CR42","doi-asserted-by":"publisher","first-page":"6698","DOI":"10.1016\/j.biomaterials.2014.05.008","volume":"35","author":"AJ Sawyer","year":"2014","unstructured":"Sawyer AJ, Tian W, Saucier-Sawyer JK, Rizk PJ, Saltzman WM, Bellamkonda RV, et al. The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation. Biomaterials. 2014;35(25):6698\u2013706.","journal-title":"Biomaterials."},{"issue":"4","key":"1608_CR43","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.bbrc.2016.12.034","volume":"482","author":"W Liu","year":"2017","unstructured":"Liu W, Gao Y, Chang N. Nurr1 overexpression exerts neuroprotective and anti-inflammatory roles via down-regulating CCL2 expression in both in vivo and in vitro Parkinson's disease models. Biochem Biophys Res Commun. 2017;482(4):1312\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1608_CR44","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/IJN.S123484","volume":"12","author":"TC Vandivort","year":"2017","unstructured":"Vandivort TC, Birkland TP, Domiciano TP, Mitra S, Kavanagh TJ, Parks WC. Stromelysin-2 (MMP-10) facilitates clearance and moderates inflammation and cell death following lung exposure to long multiwalled carbon nanotubes. Int J Nanomedicine. 2017;12:1019\u201331.","journal-title":"Int J Nanomedicine"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-1608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-020-1608-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-1608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T19:09:33Z","timestamp":1610737773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-1608-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1608"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-1608-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.14452\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14452\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14452\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.14452\/v4","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"7 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Central Committee on Research Involving Human Subjects in the region Arnhem-Nijmegen (2002\/188) and all participants provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}